Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo

Completed

• Conditions: Vitiligo

• Registration Number: NCT05037981
• Lead Sponsor: Cairo University

Brief Summary

Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most guidelines consider systemic treatments only in rapidly progressive disease with wider surface areas. This delay in halting the immune attack, may give the chance for further disease progression as well as establishment of resident memory T cell population predisposing to future disease relapses. The aim of this study was to assess the ability of early systemic therapy of localized (\<2% BSA), recent onset (\<6 months) vitiligo to control disease activity and minimize the possibility of recurrence.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10-10
• Primary Completion: 2021-08-10
• Study Completion: 2021-08-20
• Status Verified: 2021-09
• Study First Submitted: 2021-09-03
• Study First Submitted QC: 2021-09-03
• Last Update Submitted: 2021-09-03
• Study First Posted: 2021-09-08
• Last Update Posted: 2021-09-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Patients ≥ 6 years old of both genders
• Early onset vitiligo (˂6m duration)
• Body surface area (BSA) affected ≤2%

Exclusion Criteria

• Patients who received any previous treatment for vitiligo
• Pregnant and lactating females
• Patients with other cutaneous or systemic autoimmune diseases
• Patients with contraindication to systemic corticosteroids

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration needed to arrest of vitiligo activity	6 months	Time needed for vitiligo patients to stop developing new lesions of vitiligo
Duration of maintaining vitiligo stability	5 years	Time before any new vitiligo lesions reappear